Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma

This study is testing a new drug called pianzumab combined with a standard chemotherapy regimen (AVD) as a first treatment for newly diagnosed advanced classic Hodgkin lymphoma. Researchers want to see if adding pianzumab improves outcomes compared to standard therapy. **You may be eligible if...** - You are 18 to 70 years old - You have been newly diagnosed with classic Hodgkin lymphoma at an advanced stage (Stage III-IV, or Stage IIB with high-risk features) - You have not yet received any treatment for Hodgkin lymphoma - Your overall health is good enough to tolerate treatment - You have adequate heart, liver, kidney, and blood cell function **You may NOT be eligible if...** - You have nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma - Your lymphoma has spread to the brain or spinal fluid - You have an active autoimmune disease - You are HIV positive or have a history of immune deficiency - You have active tuberculosis or interstitial lung disease - You have had another cancer in the past 3 years - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.